Abstract -Aims: Genetic polymorphisms of alcohol dehydrogenase-1B (ADH1B, rs1229984) and aldehyde dehydrogenase-2 (ALDH2, rs671) affect ethanol (EtOH) metabolism and susceptibility to alcoholism. Methods: We evaluated associations between ADH1B/ALDH2 genotypes and the blood EtOH levels of 805 Japanese alcoholic men in the morning after they had drunk within the previous 34 h. Results: Age-adjusted usual alcohol consumption did not differ according to ADH1B/ALDH2 genotypes. Higher blood EtOH levels persisted for longer periods in the ADH1B*1/*1 carriers (n = 246) than in the ADH1B*2 carriers (n = 559). Blood EtOH levels did not differ by ALDH2 genotype. The blood EtOH levels ≥0.3 mg/ml (criterion for drunk driving in Japanese law) were observed (40% vs. 14-17%, P < 0.0001) in a higher proportion of the ADH1B*1/*1 carriers than of the ADH1B*2 carriers after a 12.1-to-18-h interval since the last drink. Multivariate analyses showed that the EtOH levels heightened by 0.500 mg/ml in the presence of ADH1B*1*1 and by 0.248 mg/ml in the presence of cirrhosis, and lowered by 0.120 mg/ml per 10-year age increase, by 0.087 mg/ml per 10-kg body-weight increase and by 0.673 mg/ml per 10-h interval since the last drink. The odds ratio (95% confidence interval) for an EtOH level ≥0.3 mg/ml was 3.44 (2.34-5.04) in the presence of ADH1B*1/*1, 2.01 (1.28-3.14) in the presence of cirrhosis, 0.59 (0.49-0.71) per 10-year age increase, 0.80 (0.68-0.95) per 10-kg body-weight increase and 0.10 (0.07-0.15) per 10-h interval since the last drink. Conclusion: The longer-than-expected EtOH lingering in the blood of the ADH1B*1/*1 alcoholics may exacerbate alcoholrelated problems, including drunk driving.
INTRODUCTION
Genetic polymorphisms of alcohol dehydrogenase-1B (ADH1B, rs1229984) and aldehyde dehydrogenase-2 (ALDH2, rs671) affect susceptibility to alcoholism (Higuchi et al., 1995; Chen et al., 1999; Zintzaras et al., 2006; Kim et al., 2008) . Our preliminary study investigated associations between ADH1B/ ALDH2 genotypes and the blood ethanol (EtOH) and acetaldehyde levels of nonabstinent 168 Japanese alcoholic men in the morning after drinking, and demonstrated that although there were no significant differences between the groups of patients with the various genotypes in amount of alcohol consumed in the previous 24 h and interval between blood collection and the previous drink, much higher blood EtOH and acetaldehyde levels were observed in the subjects with the slow-metabolizing ADH1B*1/*1 genotype than with the ADH1B*2 allele irrespective of their ALDH2 genotype (Yokoyama et al., 2010a) . EtOH lingering in the blood in the morning after drinking results in substantial social consequences, including lowering job productivity, drunk driving and alcohol-related accidents.
Since the effects of ADH1B/ALDH2 genotypes on blood EtOH levels after alcohol challenge tests with moderate doses of alcohol in nonalcoholics have been found to be modest at most (Thomasson et al., 1993; Yamamoto et al., 1993; Wall et al., 1997; Peng et al., 1999 Peng et al., , 2007 Neumark et al., 2004) , ADH1B/ALDH2 polymorphisms affect EtOH metabolism in heavy drinking alcoholics differently from the way they affect EtOH metabolism in nonalcoholics. EtOH oxidation is regulated by various factors, including ADH/ALDH activity, microsomal ethanol oxidizing system (MEOS) activity, hepatic redox state and acetaldehyde accumulation, all of which are affected by alcoholism (Lieber, 1995) , and altered alcohol metabolism as a result of alcoholism may modify the effects of ADH1B/ ALDH2 genotypes.
The aims of the present study were to identify the determinants of the blood EtOH levels in the morning after drinking in a large number of Japanese alcoholic men who came to our Addiction Center for the first time in the morning after drinking.
MATERIALS AND METHODS

Patients
The reference population in this study consisted of 1902 Japanese alcoholic men 40 years of age or over who met the following criteria: (a) came to the Kurihama Medical and Addiction Center for treatment of alcoholism for the first time on a morning between May 2004 and December 2011, (b) underwent routine blood tests and physical examinations including measurement of blood EtOH level and body weight on the morning of the first visit, (c) were asked about their drinking and smoking habits in a sober state and (d) underwent ADH1B and ALDH2 genotyping. On the morning of the first visit to the Addiction Center, each patient and, when available, his family, were asked to report the time when he had stopped drinking. Since the blood collection times ranged from 9:00 a.m. to 12:00 a.m., the median time, 10:30 a.m., was used as the blood collection time when calculating the interval between blood collection and the reported last drink. A total of 929 patients (48.8%) reported having drunk until the day before or today, and 805 of the 929 patients reported the time when they had stopped drinking. The 805 patients were the subjects of this study. The ethics committee of the Center reviewed and approved the proposed study (No. G37), and each of the participants gave his informed consent. Association, 1994) . We asked each patient in a sober state to report his usual daily alcohol consumption during the preceding year in terms of the amount(s) and type(s) of alcoholic beverage(s) consumed. Their usual alcohol consumption during the preceding year was expressed in grams of EtOH per day calculated by using standard conversion factors for alcoholic beverages. Beer and low-malt beer were assumed to be 5% EtOH (v/v); wine, 12%; sake, 16%; shochu, 25%; and whiskey, 40%. Daily alcohol intake was then converted to the number of units consumed per day by dividing total EtOH consumption in grams by 22 g per unit (the ethanol content of one serving of sake). The clinical diagnosis of liver cirrhosis was made on the basis of the results of the physical examination, blood tests, and imaging studies or the detection of esophagogastric varices during the endoscopic examination.
Blood EtOH levels
Blood from the antecubital vein was collected into a tube containing EDTA. The blood EtOH level was measured within 1 h of collection by absorptiometry with an autoanalyzer (COBAS INTEGRA 400 PLUS, Roche Diagnostic Ltd. Tokyo, Japan).
ADH1B and ALDH2 genotypes
Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods were performed on lymphocyte DNA samples to determine ADH1B (Xu et al., 1988) and ALDH2 (Harada and Zhang, 1993) 
RESULTS
The basic characteristics of the 805 patients who had drunk alcohol within the previous 34 h are shown in Table 1 . The slow-metabolizing ADH1B*1*1 carriers were significantly younger than the fast-metabolizing ADH1B*2 allele carriers, and the active ALDH2*1/*1 carriers were significantly younger than the inactive heterozygous ALDH2*1/*2 carriers. The frequency of liver cirrhosis was significantly lower in the ADH1B*1/*1 carriers than in the ADH1B*2 allele carriers, and in the ALDH2*1/*2 carriers than in the ALDH2*1/*1 carriers. There were no significant differences according to genotype in age-adjusted usual amount of alcohol consumed in the past year, interval between blood collection time and time of the previous drink, or age-adjusted number of cigarettes smoked. After adjustment of age, body weight and usual alcohol consumption, the mean of blood EtOH levels in the morning and the prevalence of ≥1.0 and ≥0.3 mg/ml blood EtOH levels in the morning were stratified by the interval since the previous drink according to ADH1B and ALDH2 genotypes (Table 2) . A blood EtOH level of 1.0 mg/ml was the 75th percentile level of all of the subjects as a whole and a blood EtOH level of 0.3 mg/ml is the cut-off value for 'driving under the influence of alcohol' in the Road Traffic Law of Japan. All the indexes of blood EtOH levels were consistently higher in all interval strata in the group with the ADH1B*1/*1 genotype than in the group with ADH1B*2 allele, and an interaction for blood EtOH levels was observed between ADH1B genotype and the interval since the previous drink. No such associations were found in relation to ALDH2 genotype. Blood EtOH levels ≥0.3 mg/ml were observed in 40-41% of the ADH1B*1/*1 carriers whose interval since the last drink was 12.1-24-h, and in 4-17% of the ADH1B*2 carriers. Figure 1 shows the differences in blood EtOH levels between the groups with various combinations of ADH1B and ALDH2 genotypes according to time since the last drink, after adjustment for age, body weight and usual alcohol consumption. The blood EtOH levels were significantly higher in the groups with the ADH1B*1/*1 genotype than in the ADH1B*2 carrier groups regardless of ALDH2 genotype.
Determinants of the blood EtOH levels in the morning after drinking were identified by a multiple linear regression analysis and a multiple logistic analysis (Table 3) . The results of both analyses showed that ADH1B*1/*1 genotype and presence of liver cirrhosis were strong determinants of higher blood EtOH levels, while increase in age, body weight and interval since the last drink were associated with lower blood EtOH levels. ALDH2 genotype, usual alcohol consumption and current smoking were not associated with blood EtOH levels. Blood EtOH levels in the morning after drinking heightened by 0.500 mg/ml in the presence of the ADH1B*1*1 genotype and by 0.248 mg/ml in the presence of liver cirrhosis, and the ORs (95% CI) for blood EtOH levels ≥1.0 and ≥0.3 mg/ml were 3.61 (2.40-5.41) and 3.44 (2.34-5.04), respectively, in the presence of ADH1B*1/*1 and 2.48 (1.53-4.01) and 2.01 (1.28-3.14), respectively, in the presence of liver cirrhosis. The blood EtOH levels lowered by 0.120 mg/ml per 10-year increase in age, by 0.087 mg/ml per 10-kg increase in body weight, and by 0.673 mg/ml per 10-h increase in the interval since the last drink. The ORs for blood EtOH levels ≥1.0 and ≥0.3 mg/ml were 0.66 (0.53-0.82) and 0.59 (0.49-0.71), respectively, per 10-year increase in age, 0.73 (0.60-0.88) and 0.80 (0.68-0.95), respectively, per 10-kg increase in body weight and 0.11 (0.07-0.17) and 0.10 (0.07-0.15), respectively, per 10-h increase in the interval since the last drink. 
DISCUSSION
This cross-sectional study of 805 Japanese alcoholic men who had consumed EtOH within the previous 34 h and visited the Addiction Center for the first time in the morning demonstrated that, after adjustment for age, body weight, and usual alcohol consumption and stratification according to the interval since the last drink, the blood EtOH levels of the slowmetabolizing ADH1B*1/*1 genotype carriers were much higher than in the ADH1B*2 allele carriers. Age-adjustment was essential, because usual alcohol consumption by Japanese alcoholic men has been found to decrease with age and not to significantly differ by ADH1B genotype in any of the age brackets (Yokoyama et al., 2013a) and because ADH1B*1/*1 carriers and ALDH2*1/*1 carriers were more frequent in the younger generations of alcoholics in the present study, suggesting that these alcoholism-susceptibility genotypes accelerate the progression of alcohol dependence in the younger generations. Presence of liver cirrhosis, lower body weight and younger age were also independently associated with higher blood EtOH levels of the present alcoholics. ALDH2 genotype was not associated with blood EtOH levels in the morning after drinking. Although alcohol consumption just before the first visit to the Addiction Center was not evaluated in the present study, our earlier studies demonstrated that the amount of EtOH consumed by the ADH1B*1/*1 alcoholics and ADH1B*2 alcoholics in the 24 h before the first visit was similar (Yokoyama et al., 2007 (Yokoyama et al., , 2010a , and the present study showed no significant differences in the age-adjusted usual amount of EtOH consumed in the past year according to ADH1B genotype. These findings suggest that the age-adjusted difference in the blood EtOH levels between the ADH1B*1/*1 alcoholics and the ADH1B*2 alcoholics was attributable to the difference in EtOH elimination rate rather than a low-potential difference in alcohol consumption before the first visit.
The ADH1B*1/*1 isozyme has an~40 times slower EtOH oxidation Vmax than the ADH1B*2/*2 isozyme (Yin et al., 1984) . However, alcohol challenge tests with moderate EtOH doses in nonalcoholics (Thomasson et al., 1993; Yamamoto et al., 1993; Neumark et al., 2004; Peng et al., 2007) and alcoholics after abstinence or moderation of their drinking (Chen et al., 2009) have shown that the effects of ADH1B genotype on the EtOH elimination rate are modest at most. The modest difference (11-18%; Neumark et al., 2004) in EtOH elimination rate according to ADH1B genotype may result in great differences in EtOH levels during the metabolism of large amounts of EtOH chronically consumed by alcoholics.
Japanese alcoholic men with the ADH1B*2 allele have been found to have lower body weights than Japanese male alcoholic ADH1B*1/*1 genotype carriers (Yokoyama et al., 2013a) . Alcohol calories are a major energy source and a strong modifier of body weight in alcoholics, and the faster EtOH elimination that is associated with the ADH1B*2 allele may result in more inefficient utilization of EtOH as an energy source. EtOH oxidation by induction of MEOS contributes to energy wasting through increased thermogenesis without ATP synthesis as well as to faster EtOH elimination (Lieber, 1991 (Lieber, , 1999 . A survey of 1902 Japanese alcoholic men demonstrated higher age-adjusted ORs for liver cirrhosis and chronic calcific pancreatitis in the ADH1B*2 allele carriers than in ADH1B*1/ *1 genotype carriers (Yokoyama et al., 2013b) . Further studies are needed to evaluate interactions of MEOS induction and ADH1B genotype for EtOH elimination, body weight and comorbidities in alcoholics.
Our earlier studies demonstrated high blood acetaldehyde levels (10-50 μM) in many nonabstinent ALDH2*1/*1 alcoholics (Yokoyama et al., 2007 (Yokoyama et al., , 2010a . This finding is consistent with the results of alcohol challenge tests in Western nonabstinent alcoholics (Palmer and Jenkins, 1882; Nuutinen et al., 1983; Di Padova et al., 1987) and is partly explained by the alcoholism-related induction of MEOS and depression of ALDH activity. After abstaining, the elevated blood acetaldehyde levels in alcohol challenge tests (Eriksson and Peachey, 1980; Nuutinen et al., 1984; Di Padova et al., 1987; Chen et al., 2009) , the depressed hepatic and erythrocyte ALDH activity (Jenkins et al., 1984; Lin et al., 1984) and the induced MEOS activity (Lieber, 1999) of alcoholics have been found to rapidly return toward normal levels. The K m values for acetaldehyde reduction in the reverse reaction catalyzed by the ADH1B*1/*1 isozyme and ADH1B*2/*2 isozyme are 85 and 240 μM, respectively (Yin et al., 1984) . The reverse reaction may be more greatly accelerated at 10-50 μM blood acetaldehyde levels by the ADH1B*1/*1 isozyme than by the ADH1B*2 isozymes, thereby widening the difference in EtOH elimination rate according to the ADH1B genotype. A recent study of HeLa cells into which human ADH1B had been transduced showed that product inhibition by acetaldehyde markedly differed between the ADH1B isozymes (Matsumoto et al., 2011) . In the presence of 10-50 μM acetaldehyde, the EtOH oxidation activity of the ADH1B*1/*1 isozyme was markedly limited to 0-13% of the slow Vmax and that of the ADH1B*2/ *2 isozyme to 20-45% of the fast Vmax in comparison with their activity in the absence of acetaldehyde.
Since excessive EtOH ingestion can lead to a marked increase in liver NADH beyond the ability of NADH reoxidation, the ability of EtOH oxidation is in part regulated by product inhibition of ADH by NADH. K m and K i values of ADH1B*2/*2 enzyme for NAD + and NADH are considerably greater than the corresponding values of ADH1B*1/*1 enzyme (e.g. K i for NADH was 9.7 and 0.19 μM, respectively; Yin et al., 1984) , and the ADH1B isozymes may be differently affected by the hepatic redox shift in alcoholics.
The ADH1B*2 allele acts in a semidominant manner, and the heterozygous ADH1B*1/*2 enzyme and homozygous ADH1B*2/*2 enzyme exhibited 100 and 200 times higher in vitro activity, respectively, than the homozygous ADH1B*1/ *1 enzyme (Yin et al., 1984) . East-Asian case-control studies have shown an increased ADH1B*1-allele-associated risk of alcoholism in a dose-dependent manner as the number of ADH1B*1 alleles increases (Higuchi et al., 1995; Chen et al., 1999; Kim et al., 2008) . However, the differences in risk for alcoholism between ADH1B*1/*2 carriers and ADH1B*2/*2 carriers were much smaller than those between ADH1B*1/*1 carriers and ADH1B*2 carriers and did not reach the level of statistical significance except among ALDH2*1/*1 carriers in a Japanese study conducted by Higuchi et al. (1995) . The present study failed to demonstrate any differences in blood EtOH levels between ADH1B*1/*2 heterozygotes and ADH1B*2/*2 homozygotes (Table 2) . This is partly attributable to the modest difference in kinetic properties between the ADH1B*1/*2 enzyme and ADH1B*2/*2 enzyme.
The usual volume of EtOH consumed and frequency of drinking are generally much lower in ALDH2*1/*2 carriers than in ALDH2*1/*1 carriers (Matsuo et al., 2006) . The results of an alcohol challenge test of 93 healthy male Japanese have showed a 7% slower EtOH elimination rate after moderate drinking in an ALDH2*1/*2 carrier group than in an ALDH2*1/*1 carrier group (Yamamoto et al., 1993) , possibly due to product inhibition of an EtOH oxidation by acetaldehyde. Similar results have been reported in other Asian studies (Thomasson et al., 1993; Luu et al., 1995; Peng et al., 1999) , but the absence of any significant differences in results has also been reported (Wall et al., 1997; Peng et al., 2007) , and the discrepancies may be attributable to group differences in important variables, especially history of alcohol use (Wall et al., 1997) . In the present study the ALDH2 genotype had no impact on the blood EtOH levels of the alcoholics. Alcohol flushing diminishes in intensity as a result of the development of tolerance to acetaldehydemia in alcoholics (Yokoyama et al., 2010b) . Since high blood acetaldehyde levels have been observed in nonabstinent alcoholics irrespective of ALDH2 genotype (Yokoyama et al., 2007 (Yokoyama et al., , 2010a and current usual alcohol consumption did not differ according to ALDH2 genotype, the ALDH2-associated effect on EtOH elimination may be masked in alcoholics.
Male Caucasian drunk-driving traffic offenders have been reported to be more likely to have the ADH1B*1/*1 genotype than the ADH1B*2 allele (Pavanello et al., 2012) . In a 6-prefecture survey in Japan approximately half of male drunk-driving offenders were classified as 'suspicion of alcohol dependence' based on the results of the Alcohol Use Disorders Identification Test (Higuchi et al., 2009) . In the present study, a blood EtOH level ≥0.3 mg/ml, the drunkdriving criterion in Japanese law, was measured in about 40% of the ADH1B*1/*1 alcoholics even 12.1-24-h since the last drink, suggesting that the ADH1B*1/*1 genotype probably enhances the risk of drunk driving in alcoholics because of the longer-than-expected EtOH lingering in the blood.
Body weight was significantly higher and the frequency of liver cirrhosis significantly lower in the ADH1B*1/*1 carriers than in the ADH1B*2 carriers. The shorter interval since the previous drink was also related to the higher EtOH levels. We used three approaches to decrease the potential confounding effects. First, we stratified intervals since the previous drink to compare adjusted blood EtOH concentrations according to ADH1B genotype, and the results showed that the difference in blood EtOH levels remained significant in all interval strata. Second, we compared combinations of ADH1B and ALDH2 genotypes, and the results showed that the adjusted mean EtOH levels and the adjusted prevalence of high EtOH values in the ADH1B*1/*1 carriers were higher than in the ADH1B*2 carriers regardless of the ALDH2 genotype. Third, we performed multivariate analyses including the interval time and other factors. The results obtained by these three approaches clearly demonstrated that the ADH1B*1*1 genotype was independently related to the much longer and higher exposure to EtOH the next morning in the alcoholics. The present results were based on an analysis of data obtained at only a single point in time in each individual. The results might have been more reliable if the blood EtOH levels of each individual had been monitored at several points over at least a couple of hours.
In conclusion, alcoholic ADH1B*1/*1 carriers were found to have higher blood EtOH levels and longer EtOH lingering in their blood in the morning than alcoholic ADH1B*2 carriers did. Chronic heavy drinking and/or alterations in alcohol metabolism as a result of alcoholism modify gene effects. The longer-than-expected EtOH lingering in the blood of the ADH1B*1/*1 alcoholics may exacerbate alcohol-related problems, including drunk driving.
